04:59:44 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-01-29 Bokslutskommuniké 2024
2024-10-29 Kvartalsrapport 2024-Q3
2024-08-30 Kvartalsrapport 2024-Q2
2024-05-28 Årsstämma 2024
2024-05-17 X-dag ordinarie utdelning ZICC 0.00 SEK
2024-04-29 Kvartalsrapport 2024-Q1
2024-01-26 Bokslutskommuniké 2023
2023-10-25 Kvartalsrapport 2023-Q3
2023-07-18 Kvartalsrapport 2023-Q2
2023-06-21 X-dag ordinarie utdelning ZICC 0.00 SEK
2023-06-20 Årsstämma 2023
2023-04-26 Kvartalsrapport 2023-Q1
2023-01-27 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-04-29 X-dag ordinarie utdelning ZICC 0.00 SEK
2022-04-28 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2022-01-18 Extra Bolagsstämma 2022
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-04-28 X-dag ordinarie utdelning ZICC 0.00 SEK
2021-04-27 Årsstämma 2021
2021-04-23 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-11-06 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-17 X-dag ordinarie utdelning ZICC 0.00 SEK
2020-06-16 Årsstämma 2020
2020-04-17 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-20 Årsstämma 2019
2019-05-10 X-dag ordinarie utdelning ZICC 0.00 SEK
2019-05-09 Kvartalsrapport 2019-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Ziccum är ett svenskt läkemedelsbolag som utvecklar nya beredningar av biologiska läkemedel. Med bolagets patenterade teknologi LaminarPace utvecklas torra beredningsformer av produkter som i nuläget finns i vätskeform. Störst verksamhet återfinns runtom Norden, samt utöver huvudverksamheten erbjuder bolaget diverse relaterade produkter. Bolagets huvudkontor ligger i Lund.
2024-06-03 16:30:00

On 27 April 2021, the Annual General Meeting of Ziccum AB (publ) ("Ziccum" or the "Company") resolved on a directed issue of not more than 46,000 employee stock options of series LTI 2021:1 (the "Stock Options") to certain employees and consultants in the Company. Today, Ziccum announces that 14,819 warrants of series 2021/2024 (the "Warrants"), related to LTI 2021:1, have been exercised for subscription of 23,709 new shares in the Company.

At the Annual General Meeting of Ziccum on 27 April 2021, it was resolved to adopt a long-term incentive program directed to senior executives and key employees in the Company, whereby 42,456 Stock Options were subscribed, of which 14,819 Stock Options have been exercised by the participants in the incentive program who, in accordance with the terms and conditions of LTI 2021:1, are entitled to exercise the Stock Options for allotment of Warrants, which in turn entitle the holder to subscribe for new shares in the Company. Each Stock Option entitles the holder to acquire one Warrant, which in turn entitles the holder to subscribe for, after recalculation in accordance with the terms and conditions of the Warrants, 1.60 new shares in the Company during the exercise period running from and including 1 May 2024 up to and including 31 May 2024, at a subscription price per share corresponding to SEK 0.17. All non-expired Stock Options have been exercised for allotment of Warrants.

The Warrants have been exercised by the Company's Scientific Director Fabrice Rose for subscription of 6,691 shares, the Company's Technical Operations Manager Rasmus Lund for subscription of 6,836 shares and the Company's former CFO Frida Hjelmberg for subscription of 10,182 shares.

A total of 14,819 Warrants have thereby been exercised for subscription of 23,709 new shares in the Company, which means that Ziccum will receive SEK 4,030.53. The exercise of the Warrants means that the Company’s share capital will increase by SEK 3,951.50, from SEK 2,562,043.000003 to SEK 2,565,994.500003, and the number of shares in the Company will increase by 23,709 shares, from 15,372,258 shares to 15,395,967 shares, corresponding to a dilution effect of approximately 0.15 percent of the number of shares and votes in the Company.